AU2016358257B2 - Virulence attenuated bacteria for treatment of malignant solid tumors - Google Patents

Virulence attenuated bacteria for treatment of malignant solid tumors Download PDF

Info

Publication number
AU2016358257B2
AU2016358257B2 AU2016358257A AU2016358257A AU2016358257B2 AU 2016358257 B2 AU2016358257 B2 AU 2016358257B2 AU 2016358257 A AU2016358257 A AU 2016358257A AU 2016358257 A AU2016358257 A AU 2016358257A AU 2016358257 B2 AU2016358257 B2 AU 2016358257B2
Authority
AU
Australia
Prior art keywords
proteins
protein
virulence attenuated
strain
recombinant virulence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016358257A
Other languages
English (en)
Other versions
AU2016358257A1 (en
Inventor
Marlise AMSTUTZ
Guy R. Cornelis
Simon ITTIG
Christoph Kasper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of AU2016358257A1 publication Critical patent/AU2016358257A1/en
Application granted granted Critical
Publication of AU2016358257B2 publication Critical patent/AU2016358257B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016358257A 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors Active AU2016358257B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15195490.6 2015-11-19
EP15195490 2015-11-19
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Publications (2)

Publication Number Publication Date
AU2016358257A1 AU2016358257A1 (en) 2018-05-10
AU2016358257B2 true AU2016358257B2 (en) 2023-08-17

Family

ID=54697464

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016358257A Active AU2016358257B2 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Country Status (24)

Country Link
US (1) US11166987B2 (enExample)
EP (2) EP3903813A1 (enExample)
JP (1) JP7060503B2 (enExample)
KR (1) KR102736981B1 (enExample)
CN (1) CN108472348B (enExample)
AU (1) AU2016358257B2 (enExample)
BR (2) BR122023024697A2 (enExample)
CA (1) CA3003563A1 (enExample)
CY (1) CY1124564T1 (enExample)
DK (1) DK3377094T3 (enExample)
EA (1) EA201890868A1 (enExample)
ES (1) ES2880431T3 (enExample)
HR (1) HRP20211191T1 (enExample)
HU (1) HUE055132T2 (enExample)
IL (1) IL259052B2 (enExample)
LT (1) LT3377094T (enExample)
PL (1) PL3377094T3 (enExample)
PT (1) PT3377094T (enExample)
RS (1) RS62152B1 (enExample)
SG (1) SG11201803643TA (enExample)
SI (1) SI3377094T1 (enExample)
SM (1) SMT202100423T1 (enExample)
WO (1) WO2017085233A1 (enExample)
ZA (1) ZA201803902B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6797025B2 (ja) 2014-05-21 2020-12-09 ウニヴェルズィテート バーゼル 細菌に基づくタンパク質送達
KR102689434B1 (ko) 2015-11-19 2024-07-29 우니페르시테트 바젤 박테리아-기반의 단백질 전달
JP6976351B2 (ja) 2016-12-20 2021-12-08 ウニヴェルズィテート・バーゼルUniversitat Basel 弱毒化細菌に基づくタンパク質送達
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
AU2021370840A1 (en) * 2020-10-27 2023-06-22 T3 Pharmaceuticals Ag Bacteria based protein delivery
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用
CN116064877B (zh) * 2023-02-09 2024-09-20 宁夏大学 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法
CN116855496B (zh) * 2023-07-05 2024-08-16 郑州大学 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用
WO2025037284A2 (en) * 2023-08-17 2025-02-20 Baccine Ltd. Genetically modified bacteria for multi-modal secretion of a neoantigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077249A2 (en) * 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
US7763420B2 (en) * 2006-07-11 2010-07-27 Genelux Corporation Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU5209399A (en) 1998-07-10 2000-02-01 Cornell Research Foundation Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
WO2007044406A2 (en) 2005-10-04 2007-04-19 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
AU2009226972B2 (en) 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
DK2717886T3 (da) 2011-06-08 2021-12-06 Chelation Partners Incorporated Metalchelateringssammensætninger og fremgangsmåder til styring af en levende celles eller organismes vækst eller aktiviteter
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
JP6797025B2 (ja) 2014-05-21 2020-12-09 ウニヴェルズィテート バーゼル 細菌に基づくタンパク質送達
KR102689434B1 (ko) 2015-11-19 2024-07-29 우니페르시테트 바젤 박테리아-기반의 단백질 전달
JP6976351B2 (ja) 2016-12-20 2021-12-08 ウニヴェルズィテート・バーゼルUniversitat Basel 弱毒化細菌に基づくタンパク質送達

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077249A2 (en) * 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
US7763420B2 (en) * 2006-07-11 2010-07-27 Genelux Corporation Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fensterle, J. et al., Cancer Gene Therapy, (2008-02-01), vol. 15, no. 2, pages 85 - 93, DOI: 10.1038/SJ.CGT.7701109. *
Gentschev, I. et al., BMC Cancer, (2005-02-09), vol. 5, no. 1, pages 1-9-, DOI: 10.1186/1471-2407-5-15. *
Wiedig, C. et al., 'Induction of CD8+T cell responses by Yersinia vaccine carrier strains', Vaccine, (2005), Vol. 23(42), pages 4984 - 4898, ISSN: 0004561914. *

Also Published As

Publication number Publication date
EA201890868A1 (ru) 2018-12-28
CN108472348B (zh) 2022-12-27
HRP20211191T1 (hr) 2021-10-29
KR20180081583A (ko) 2018-07-16
US20190015497A1 (en) 2019-01-17
BR122023024697A2 (pt) 2023-12-26
DK3377094T3 (da) 2021-08-02
EP3903813A1 (en) 2021-11-03
AU2016358257A1 (en) 2018-05-10
BR112018009753A8 (pt) 2019-02-26
US11166987B2 (en) 2021-11-09
KR102736981B1 (ko) 2024-12-02
ES2880431T3 (es) 2021-11-24
EP3377094B1 (en) 2021-04-28
LT3377094T (lt) 2021-08-10
BR112018009753A2 (pt) 2018-11-13
JP7060503B2 (ja) 2022-04-26
PT3377094T (pt) 2021-07-08
JP2019500026A (ja) 2019-01-10
HK1256137A1 (en) 2019-09-13
SMT202100423T1 (it) 2021-09-14
IL259052A (en) 2018-07-31
IL259052B1 (en) 2023-11-01
BR112018009753B1 (pt) 2024-02-20
WO2017085233A1 (en) 2017-05-26
IL259052B2 (en) 2024-03-01
EP3377094A1 (en) 2018-09-26
CY1124564T1 (el) 2022-07-22
PL3377094T3 (pl) 2021-12-13
CA3003563A1 (en) 2017-05-26
HUE055132T2 (hu) 2021-11-29
SI3377094T1 (sl) 2021-09-30
ZA201803902B (en) 2019-03-27
CN108472348A (zh) 2018-08-31
RS62152B1 (sr) 2021-08-31
SG11201803643TA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
AU2016358257B2 (en) Virulence attenuated bacteria for treatment of malignant solid tumors
US12358955B2 (en) Virulence attenuated bacteria based protein delivery
US20240401065A1 (en) Bacteria-Based Protein Delivery
AU2016355975B2 (en) Bacteria-based protein delivery
HK1256137B (en) Virulence attenuated bacteria for treatment of malignant solid tumors
EA040558B1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
HK40015324A (en) Virulence attenuated bacteria based protein delivery
HK40015324B (en) Virulence attenuated bacteria based protein delivery
HK1256138B (en) Bacteria-based protein delivery
HK1236208B (en) Bacteria-based protein delivery
HK1236208A1 (en) Bacteria-based protein delivery

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)